Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
Abstract
Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid, e.g., oleic acid, that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound or active metabolite thereof to subcutaneous fat under the skin. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. The present invention also provides kits comprising the composition and instructions for use.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A composition comprising latanoprost and oleic acid.
20 . The composition of claim 19 , wherein latanoprost concentration is between about 0.05 percent and about 0.5 percent, inclusive, by weight of the total weight of the composition.
21 . The composition of claim 19 , wherein the composition comprises between about 1 percent and about 20 percent of oleic acid, inclusive, by weight of the total weight of the composition.
22 . The composition of claim 21 , wherein the composition comprises between about 1 percent and about 5 percent oleic acid, inclusive, by weight of the total weight of the composition.
23 . The composition of claim 22 , wherein the composition comprises between about 2 percent and about 4 percent oleic acid, inclusive, by weight of the total weight of the composition.
24 . The composition of claim 19 , further comprising propylene glycol.
25 . The composition of claim 24 , wherein the composition comprises between about 5 percent and about 50 percent of propylene glycol, inclusive, by weight of the total weight of the composition.
26 . The composition of claim 25 , wherein the composition comprises between about 20 percent and about 30 percent of propylene glycol, inclusive, by weight of the total weight of the composition.
27 . The composition of claim 26 , wherein the composition comprises between about 25 percent and about 30 percent of propylene glycol, inclusive, by weight of the total weight of the composition.
28 . The composition of claim 27 , wherein the composition comprises about 3 percent oleic acid and about 27 percent propylene glycol by weight of the total weight of the composition.
29 . The composition of claim 19 , further comprising ethanol.
30 . The composition of claim 29 , wherein the composition comprises between about 60 percent and about 80 percent ethanol, inclusive, by weight of the total weight of the composition.
31 . The composition of claim 19 , further comprising glycerin.
32 . A method for reducing body fat in a subject in need thereof, the method comprising topically administering to the subject the composition of claim 19 .
33 . A method for reducing body fat in a subject in need thereof, the method comprising topically administering to the subject a composition comprising tafluprost and oleic acid.
34 . The method of claim 33 , comprising tafluprost, wherein tafluprost concentration is between about 0.01 percent and about 0.1 percent, inclusive, by weight of the total weight of the composition.
35 . The method of claim 33 , wherein the composition comprises between about 1 percent and about 20 percent of oleic acid, inclusive, by weight of the total weight of the composition.
36 . The method of claim 33 , wherein the composition further comprises propylene glycol.
37 . The method of claim 36 , wherein the composition comprises between about 5 percent and about 50 percent of propylene glycol, inclusive, by weight of the total weight of the composition.Join the waitlist — get patent alerts
Track US2021213032A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.